<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NAFTIN- naftifine hydrochloride gel </strong><br>Merz Pharmaceuticals, LLC<br></p></div>
<h1>NAFTIN<span class="Sup">®</span><br> NAFTIFINE HCl 1%</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First">Rx ONLY</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Naftin<span class="Sup">®</span> Cream, 1% and Naftin<span class="Sup">®</span> Gel, 1% contain the synthetic, broad-spectrum, antifungal agent naftifine hydrochloride. Naftin<span class="Sup">®</span> Cream and Gel, 1% are for topical use only.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<h2>CHEMICAL NAME</h2>
<p class="First">(E)-N-Cinnamyl-N-methyl-1-naphthalenemethylamine hydrochloride.  Naftifine hydrochloride has an empirical formula of C<span class="Sub">21</span>H<span class="Sub">21</span>N•HCl and a molecular weight of 323.86.</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e516fb5a-5c9b-4a74-9beb-423f2b345dde&amp;name=naftin-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<h2>Contains</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.1"></a><p></p>
<h3>Active Ingredient</h3>
<table class="Noautorules" width="50%">
<col align="left" valign="top" width="60%">
<col align="left" valign="top" width="40%">
<tbody class="Headless"><tr>
<td align="left">Naftifine hydrochloride</td>
<td align="left">1%.</td>
</tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.2"></a><p></p>
<h3>Inactive Ingredients</h3>
<p class="First">Naftin<span class="Sup">®</span> Cream, 1% contains benzyl alcohol, cetyl alcohol, cetyl esters wax, isopropyl myristate, polysorbate 60, purified water, sodium hydroxide, sorbitan monostearate, and stearyl alcohol. Hydrochloric acid may be added to adjust pH. Naftin<span class="Sup">®</span> Gel, 1% contains polysorbate 80, carbomer 934P, diisopropanolamine, edetate disodium, alcohol (52%v/v), and purified water.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Naftifine Hydrochloride is a synthetic allylamine derivative. The following <span class="Italics">in vitro</span> data are available but their clinical significance is unknown. Naftifine hydrochloride has been shown to exhibit fungicidal activity <span class="Italics">in vitro</span> against a broad spectrum of organisms, including <span class="Italics">Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Epidermophyton floccosum, Microsporum canis, Microsporum audouini,</span> and <span class="Italics">microsporum gypseum,</span> and fungistatic activity against <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> species, including <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans.</span> Naftin<span class="Sup">®</span> Cream and Gel, 1% have only been shown to be clinically effective against the disease entities listed in the <a href="#INDICATIONS">INDICATIONS AND USAGE</a> section.</p>
<p>Although the exact mechanism of action against fungi is not known, naftifine hydrochloride appears to interfere with sterol biosynthesis by inhibiting the enzyme squalene 2, 3-epoxidase. This inhibition of enzyme activity results in decreased amounts of sterols, especially ergosterol, and a corresponding accumulation of squalene in the cells.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First"><span class="Italics">In vitro</span> and <span class="Italics">in vivo</span> bioavailability studies have demonstrated that naftifine penetrates the stratum corneum in sufficient concentration to inhibit the growth of dermatophytes.</p>
<p>Following a single topical application of 1% of naftifine cream to the skin of healthy subjects, systemic absorption of naftifine was approximately 6% of the applied dose. Following single topical applications of <span class="Sup">3</span>H- labeled naftifine gel 1% to the skin of healthy subjects, up to 4.2% of the applied dose was absorbed. Naftifine and/or its metabolites are excreted via the urine and feces with a half-life of approximately two to three days.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="INDICATIONS"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Naftin<span class="Sup">®</span> Cream, 1% is indicated for the topical treatment of <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span>, <span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">tinea cruris</span>, and <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> corporis caused by the organisms <span class="Italics">Trichophyton rubrum, Trichophyton mentagrophytes,</span> and <span class="Italics">Epidermophyton floccosum</span>. Naftin<span class="Sup">®</span> Gel, 1% is indicated for the topical treatment of <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span>, <span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">tinea cruris</span>, and <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> corporis caused by the organisms <span class="Italics">Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans<a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a></span>, <span class="Italics">Epidermophyton floccosum<a href="#footnote-1" class="Sup">1</a></span>.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd>Efficacy for this organism in this organ system was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Naftin<span class="Sup">®</span> Cream and Gel, 1% are contraindicated in individuals who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of their components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Naftin<span class="Sup">®</span> Cream and Gel, 1% are for topical use only and not for ophthalmic use.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Naftin<span class="Sup">®</span> Cream and Gel, 1%, are for external use only. If irritation or sensitivity develops with the use of Naftin<span class="Sup">®</span> Cream or Gel, 1%, treatment should be discontinued and appropriate therapy instituted. Diagnosis of the disease should be confirmed either by direct microscopic examination of a mounting of infected tissue in a solution of potassium hydroxide or by culture on an appropriate medium.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>Information for patients</h2>
<p class="First">The patient should be told to:</p>
<ol class="Arabic">
<li>Avoid the use of occlusive dressings or wrappings unless otherwise directed by the physician.</li>
<li>Keep Naftin<span class="Sup">®</span> Cream and Gel, 1% away from the eyes, nose, mouth and other mucous membranes.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, mutagenesis, impairment of fertility</h2>
<p class="First">Long-term studies to evaluate the carcinogenic potential of Naftin<span class="Sup">®</span> Cream and Gel, 1% have not been performed. <span class="Italics">In vitro</span> and animal studies have not demonstrated any mutagenic effect or effect on fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.4"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.4.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4.1.1"></a><p></p>
<h4>Pregnancy Category B</h4>
<p class="First">Reproduction studies have been performed in rats and rabbits (via oral administration) at doses 150 times or more than the topical human dose and have revealed no evidence of impaired fertility or harm to the fetus due to naftifine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.5"></a><p></p>
<h2>Nursing mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Naftin<span class="Sup">®</span> Cream or Gel,1 % are administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.6"></a><p></p>
<h2>Pediatric use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">During clinical trials with Naftin<span class="Sup">®</span> Cream, 1%, the incidence of adverse reactions was as follows: burning/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> (6%), dryness (3%), <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> (2%), <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> (2%), local irritation (2%). During clinical trials with Naftin<span class="Sup">®</span> Gel, 1%. the incidence of adverse reactions was as follows: burning Istinging (5.0%), <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> (1.0%), <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> (0.5%), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (0.5%), <span class="product-label-link" type="condition" conceptid="4115411" conceptname="Pain of skin">skin tenderness</span> (0.5%).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">A sufficient quantity of Naftin<span class="Sup">®</span> Cream, 1% should be gently massaged into the affected and surrounding skin areas once a day. A sufficient quantity of Naftin<span class="Sup">®</span> Gel, 1% should be gently massaged into the affected and surrounding skin areas twice a day, in the morning and evening. The hands should be washed after application. If no clinical improvement is seen after four weeks of treatment with Naftin<span class="Sup">®</span> Cream or Gel, 1%, the patient should be re-evaluated.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Naftin<span class="Sup">®</span> (naftifine hydrochloride) Cream. 1% is supplied in collapsible tubes in the following sizes:</p>
<dl>
<dt> </dt>
<dd>60g – NDC 0259-4126-60</dd>
<dt> </dt>
<dd>90g – NDC 0259-4126-90</dd>
</dl>
<p>Naftin<span class="Sup">®</span> (naftifine hydrochloride) Gel, 1% is supplied in collapsible tubes in the following sizes</p>
<dl>
<dt> </dt>
<dd>40g – NDC 0259-4770-40</dd>
<dt> </dt>
<dd>60g – NDC 0259-4770-60</dd>
<dt> </dt>
<dd>90g – NDC 0259-4770-90</dd>
</dl>
<div class="Section" data-sectionCode="44425-7">
<a name="section-10.1"></a><p></p>
<p class="First"><span class="Bold">Note:</span> Store Naftin<span class="Sup">®</span> Cream, 1% below 30°C (86°F).</p>
<p>Store Naftin<span class="Sup">®</span> Gel, 1% at room temperature.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<h1></h1>
<p class="First">Manufactured for <span class="Bold">Merz Pharmaceuticals, Greensboro, NC 27410</span><br>© 2011 Merz Pharmaceuticals Rev 4/11 5011418</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 90g Tube Carton</h1>
<p class="First">NDC 0259-4770-90</p>
<p><span class="Bold">NAFTIN<span class="Sup">®</span><br>90g gel</span></p>
<p><span class="Bold">NAFTIFINE HCl 1% GEL</span></p>
<p>Rx Only</p>
<p>MERZ<span class="Sup">®</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 90g Tube Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e516fb5a-5c9b-4a74-9beb-423f2b345dde&amp;name=naftin-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NAFTIN 		
					</strong><br><span class="contentTableReg">naftifine hydrochloride gel</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0259-4770</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NAFTIFINE HYDROCHLORIDE</strong> (NAFTIFINE) </td>
<td class="formItem">NAFTIFINE HYDROCHLORIDE</td>
<td class="formItem">10 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>edetate disodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Carbomer Homopolymer Type B (Allyl Sucrose Crosslinked)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Polysorbate 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Diisopropanolamine</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0259-4770-40</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">40 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0259-4770-60</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">60 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0259-4770-90</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">90 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019356</td>
<td class="formItem">10/01/1990</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Merz Pharmaceuticals, LLC
							(126209282)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f62fc834-0f0b-4dd2-a2d9-a49274e51e34</div>
<div>Set id: e516fb5a-5c9b-4a74-9beb-423f2b345dde</div>
<div>Version: 5</div>
<div>Effective Time: 20130425</div>
</div>
</div> <div class="DistributorName">Merz Pharmaceuticals, LLC</div></p>
</body></html>
